| Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy : results of SAKK 11/16, a phase IIa trial | Experimental hematology & oncology |  | | 2025 | 71 | 112 |
|
| A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors | Cancer research communications | | | 2024 | 119 | 246 |
|
| LBA46 SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy | ESMO Congress 2023 | | | 2023 | 132 | 183 |
|
| Engineering a versatile and retrievable cell macroencapsulation device for the delivery of therapeutic proteins | iScience | | | 2023 | 110 | 79 |
|
| Sustained delivery of low-dose anti-CTLA-4 by genetically engineered encapsulated cells to the tumor microenvironment drives tumor response and prolongs survival in a colorectal cancer model | AACR Annual Meeting 2023 | | | 2023 | 86 | 248 |
|
| Personalized immunotherapy with encapsulated cell technology : Feasibility, safety and efficacy results from the first-in-human clinical trial in advanced relapsing solid tumors | ESMO Congress 2022 | | | 2022 | 100 | 210 |
|
| Immortalised human myoblast cell lines for the delivery of therapeutic proteins using encapsulated cell technology | Molecular therapy. Methods & clinical development | | | 2022 | 257 | 189 |
|
